In This Article:
Key Points
-
Shares of Amgen have rallied at the start of 2025 despite the broader stock market sell-off.
-
Amgen benefits from its portfolio of best-in-class therapeutics, alongside an extensive pipeline.
-
The stock's 3.3% dividend yield looks compelling, backed by…